Mr. Luc Tanguay reports
THERATECHNOLOGIES OBTAINS US PATENT FOR IMPROVING COGNITIVE FUNCTION WITH TESAMORELIN IN PATIENTS SUFFERING FROM MCI
The U.S. Patent and Trademark Office has issued patent No. 8,481,489 entitled, "GH Secretagogues and Uses Thereof," covering a method of improving cognitive function in a subject suffering from mild cognitive impairment through the administration of tesamorelin. The patent will expire in 2024.
"We are glad the USPTO delivered this patent as it enlarges the protection of tesamorelin for use in a potential therapeutic area," stated Luc Tanguay, president and chief executive officer of Theratechnologies Inc.
© 2013 Canjex Publishing Ltd. All rights reserved.